VBI Vaccines Inc. VBIV introduced that it has initiated a section I/II examine to judge its monovalent enveloped virus-like particle (eVLP) COVID-19 vaccine candidate — VBI-2902. The vaccine candidate is being developed significantly for immunization in opposition to SAR-CoV-2, the virus f www.nasdaq.com
VBI Vaccines Inc. VBIV introduced that it has initiated a section I/II examine to judge its monovalent enveloped virus-like particle (eVLP) COVID-19 vaccine candidate — VBI-2902. The vaccine candidate is being developed significantly for immunization in opposition to SAR-CoV-2, the virus f
www.nasdaq.com